Publications by authors named "Aimin Hui"

Claim this Profile
P
Phase 1 Study of Luvometinib Use in Pediatric Patients with Neurofibromatosis Type 1-Related Unresectable Plexiform Neurofibromas.
Xiaojie Hu, Zhuli Wu, Jinhu Wang, Wenbin Li, Kang Zeng, Yaohui Ma, Ai-Min Hui

Target Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial.
Qiao Li, Ying Cheng, Zhongsheng Tong, Yunjiang Liu, Xian Wang, Ai-Min Hui

Nat Commun· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-informed dose selection for an investigational human epidermal growth factor receptor 2 antibody-drug conjugate FS-1502 in patients with human epidermal growth factor receptor 2-expressing advanced malignant solid tumours.
Yi Sun, Chao Li, Xingli Wang, Yi Zheng, Zhuli Wu, Ai-Min Hui

Br J Clin Pharmacol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Safety, and Tolerability of Tenapanor in Healthy Chinese and Caucasian Volunteers: A Randomized, Open-Label, Single-Center, Placebo-Controlled Phase 1 Study.
Gang Yuan, Yili Chen, Li Li, Xin Wang, Gang Wei, Ai-Min Hui

Int J Clin Pract· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of High-Fat Food on the Pharmacokinetic Profile and Safety of SAF-189s, an ALK/ROS1 Inhibitor, in Healthy Chinese Adults.
Huiling Qin, Yan Tan, Lei Diao, Ai-Min Hui, Zhuli Wu

Drugs R D· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China.
Heng Mei, Hu Zhou, Ming Hou, Jing Sun, Lei Zhang, Hui Wang, Aimin Hui

Res Pract Thromb Haemost· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas.
Xiaojie Hu, Wenbin Li, Kang Zeng, Zhongyuan Xu, Changxing Li, Ai-Min Hui

BMC Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males.
Jiangfan Li, Yan Tan, Kexin Li, Ai-Min Hui, Zhuli Wu

Adv Ther· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.
Ai-Min Hui, Jingxin Li, Li Zhu, Rong Tang, Huayue Ye

Lancet Reg Health West Pac· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma.
Lili Mao, Jun Guo, Lingjun Zhu, Yu Jiang, Wangjun Yan, Ai-Min Hui

Eur J Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors.
Amita Patnaik, Erika Hamilton, Yan Xing, Drew W Rasco, Lon Smith, Ai-Min Hui

Cancers (Basel)· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis.
Lingxiao Zhang, Liangying Gan, Kexin Li, Panpan Xie, Yan Tan, Ai-Min Hui

Eur J Clin Pharmacol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial.
Jingxin Li, Ai-Min Hui, Xiang Zhang, Lei Ge, Yuanzheng Qiu

Adv Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Delivery of mRNA Vaccines for Therapeutics.
Nitika, Jiao Wei, Ai-Min Hui

Life (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney Disease.
Liangying Gan, Panpan Xie, Yan Tan, Gang Wei, Xiaojuan Yuan, Ai-Min Hui

Drugs R D· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines.
Jiao Wei, Ai-Min Hui

Cancer Treat Rev· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: Results of a phase I single dose escalation study.
Yue Liu, Yan Tan, Gang Wei, Zhifei Lu, Yazhou Liu, Ai-Min Hui

Pulm Pharmacol Ther· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avatrombopag ethnic sensitivity analysis in chronic liver disease and thrombocytopenia patients: individual-level pooled analysis.
Jun Lu, Brian D Jamieson, Ai-Min Hui

Therap Adv Gastroenterol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
Lin Lin, Hongming Pan, Xingya Li, Chengling Zhao, Jiangtao Sun, Ai-Min Hui, Huilong Liu

Lung Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study.
Duanduan Cong, Jie Song, Yue Liu, Yan Tan, Wei Xue, Xiaohui Liu, Ai-Min Hui

Neurol Ther· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Biomarkers in FLT3 AML.
Nitika, Jiao Wei, Ai-Min Hui

Cancers (Basel)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of Ribosome Interactions with SARS-CoV-2 and COVID-19 mRNA Vaccine.
Jiao Wei, Aimin Hui

Life (Basel)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1a study of the CDK4/6 inhibitor, FCN-437c, in Chinese patients with HR + /HER2- advanced breast cancer.
Jian Zhang, Xiaojia Wang, Xian Wang, Aimin Hui, Zhuli Wu

Invest New Drugs· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Development of mRNA Vaccines for Infectious Diseases: Recent Updates.
Nitika, Jiao Wei, Ai-Min Hui

Infect Drug Resist· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19.
Rui-Ru Ji, Yajin Qu, Hua Zhu, Yumei Yang, Annette B Vogel, Aimin Hui

Vaccines (Basel)· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis